ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma Clinical Trial

— ACVDL  

Official title:

An Open-Label Phase II Study of the Safety and Efficacy of Doxorubicin and Cyclophosphamide in Combination With Bortezomib, Lenalidomide, and Dexamethasone for Treatment of Patients With Newly Diagnosed Multiple Myeloma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01481194
• Other study ID #: SDU/VS-HKU/CTC-2011-01
• Status: Completed
• Phase: Phase 2
• Start date: November 2011
• Est. completion date: August 28, 2018

Study information

• Verified date: February 2019
• Source: Vejle Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of the combination treatment of doxorubicin, cyclophosphamide, bortezomib, dexamethasone, and lenalidomide in newly diagnosed multiple myeloma patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: August 28, 2018
• Est. primary completion date: May 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female subjects = 18 years at the time of signing informed consent.

2. Subject is diagnosed with symptomatic multiple myeloma based on the International Myeloma Working Group Diagnostic Criteria (Kyle 2009):

• Monoclonal plasma cells in the bone marrow = 10% and/or presence of a biopsy-proven plasmacytoma.

• Monoclonal protein present in the serum and/or urine. If no monoclonal protein is detected (non-secretory disease), then = 30% monoclonal bone marrow plasma cells and/or a biopsy-proven plasmacytoma is required.

• Myeloma-related organ dysfunction

3. The myeloma disease burden must be measurable with at least one of the following criteria (Durie et al. 2006):

• Serum M-protein = 10 g/l

• Urine M-protein = 200 mg/24 h

• Involved FLC = 100 mg/l provided serum FLC ratio is abnormal

• Bone marrow plasma cells > 30%

4. Subject has a Karnofsky performance status of = 60.

5. Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.

6. Subject is willing and able to comply with the protocol as judged by the investigator.

Exclusion Criteria:

1. Any prior systemic therapy for multiple myeloma.

2. Other therapies such as biologic therapy and chemotherapy less than 3 months prior to screening.

3. Any prior treatment with doxorubicin or other anthracycline.

4. Concurrent or recent (less than 2 weeks prior to Screening) radiotherapy or surgery.

5. Prior glucocorticoid treatment of multiple myeloma exceeding dexamethasone 20mg/day for a maximum of 7 days. Topical glucocorticosteroid therapy to treat non-malignant comorbid disorders is permitted.

6. More than or equal to grade 2 peripheral neuropathy according to the NCI-CTC criteria on clinical examination within 14 days before enrolment (Day 1 of Cycle 1).

7. Evidence of mucosal or internal bleeding and/or platelet counts < 50 x 10^9/l. Platelet transfusions may not be used to meet PLT eligibility criteria.

8. Absolute neutrophil count (ANC) < 1 x 10^9/l. Growth factors may not be used to meet ANC eligibility criteria.

9. Hemoglobin < 5.0 mmol/l. The subject may be included after correction of the hemoglobin level by transfusion or treatment with erythropoietin.

10. Alanine aminotransferase (ALAT) > 2 x ULN.

11. Myocardial infarction within 6 months prior to enrolment or New York Heart Association (NYHA) Class IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant.

12. Clinically relevant active infection or serious co-morbid medical conditions, such as chronic obstructive or chronic restrictive pulmonary disease, and cirrhosis.

13. Any condition, including laboratory abnormalities, that in the opinion of the Investigator places the subject at unacceptable risk if he/she were to participate in the study.

14. Prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, or in situ prostate cancer for which the subject has been disease-free for at least 3 years.

15. Female subject is pregnant or breast-feeding. The first serum pregnancy test to be done within 10-14 days prior to the study treatment start and repeated serum pregnancy test to be done within 24 hours prior to the start of study treatment.

16. Female subjects who are of childbearing potential (biologically capable of becoming pregnant) or men with partners of childbearing potential, who are unwilling or unable to use effective means of contraception. The means of contraception must be TWO acceptable methods of birth control, one highly effective method (hormonal contraceptives pills, injections or implants, tubal ligation, partner's vasectomy) and one additional effective method (condom, diaphragm, cervical cap) AT THE SAME TIME, at least 28 days before she or he starts ACVDL and for at least 28 days after the last dose of ACVDL.

17. Serious medical or psychiatric illness likely to interfere with participation in this clinical study.

18. Uncontrolled diabetes mellitus at the discretion of the investigator.

19. Hypersensitivity and/or contraindication to any one of the Investigational Medicinal Products (IMP), acyclovir or similar anti-viral drug.

20. POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes).

21. Known HIV infection.

22. Known active hepatitis B or C viral infection.

23. Known intolerance to steroid therapy.

24. Current or recent (within 30 days prior to Screening) treatment with another investigational drug.

25. Unable to comply with the administration of the study treatment.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• Doxorubicin
50 mg/m2 IV on day 1 of a 21-day cycle
• Bortezomib
1.3 mg/m2 IV push on days 2 and 9 of a 21-day cycle
• Lenalidomide
15 mg orally on days 1-14 of a 21-day cycle
• Dexamethasone
20 mg orally on days 2, 3, 9, and 10 of a 21-day cycle
• Cyclophosphamide
750 mg/m2 IV on day 1 of a 21-day cycle

Locations

Country	Name	City	State
Denmark	Department of Hematology	Vejle

Sponsors (2)

Lead Sponsor	Collaborator
Vejle Hospital	The University of Hong Kong

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response rate		4 weeks after completion of 8 treatment cycles
Secondary	Complete response rate		4 weeks after completion of 8 treatment cycles
Secondary	Very good partial response rate		4 weeks after completion of 8 treatment cycles
Secondary	Time to progression		4 years
Secondary	Progression free survival		4 years